• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TradeUP Acquisition Corp. (Amendment)

    1/31/23 12:33:26 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $UPTD alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    TradeUP Acquisition Corp.

    (Name of Issuer)

     

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    89268A107

    (CUSIP Number)

     

    December 31, 2022

     

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    CUSIP No. 89268A107  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Boothbay Fund Management, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, OO

     

     
     

     

    CUSIP No. 89268A107  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Boothbay Absolute Return Strategies LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

     
     

     

    CUSIP No. 89268A107  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Ari Glass

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    0

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    0

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

     
     

     

    Item 1.

     

      (a)

    Name of Issuer

    TradeUP Acquisition Corp. (the “Issuer”)

         
      (b)

    Address of Issuer’s Principal Executive Offices

    437 Madison Ave, 27th Floor

    New York, NY 10022

     

    Item 2.

     

      (a)

    Name of Person Filing:

    Boothbay Fund Management, LLC

    Boothbay Absolute Return Strategies LP

    Ari Glass

         
      (b)

    Address of the Principal Office or, if none, residence

    140 East 45th Street, 14th Floor

    New York, NY 10017

         
      (c)

    Citizenship

    Boothbay Fund Management, LLC – Delaware

    Boothbay Absolute Return Strategies LP – Delaware

    Ari Glass – United States

         
      (d)

    Title of Class of Securities

    Common stock

         
      (e)

    CUSIP Number

    89268A107

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: N/A

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    Boothbay Fund Management, LLC – 0

    Boothbay Absolute Return Strategies LP – 0

    Ari Glass – 0

           
      (b)

    Percent of class:

    Boothbay Fund Management, LLC – 0%

    Boothbay Absolute Return Strategies LP – 0%

    Ari Glass – 0%

     

     
     

     

      (c) Number of shares as to which the person has:
           
        (i)

    Sole power to vote or to direct the vote

    Boothbay Fund Management, LLC – 0

    Boothbay Absolute Return Strategies LP – 0

    Ari Glass – 0

           
        (ii)

    Shared power to vote or to direct the vote

    Boothbay Fund Management, LLC – 0

    Boothbay Absolute Return Strategies LP – 0

    Ari Glass – 0

           
        (iii)

    Sole power to dispose or to direct the disposition of

    Boothbay Fund Management, LLC – 0

    Boothbay Absolute Return Strategies LP – 0

    Ari Glass – 0

           
        (iv)

    Shared power to dispose or to direct the disposition of

    Boothbay Fund Management, LLC – 0

    Boothbay Absolute Return Strategies LP – 0

    Ari Glass – 0

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

    Item 10. Certification.

     

     

     

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    CUSIP No. 89268A107

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 31, 2023

     

      Boothbay Fund Management, LLC
         
      By: /s/ Ari Glass
        Ari Glass, Managing Member
         
      Boothbay Absolute Return Strategies LP
         
      By: Boothbay Fund Management, LLC,
        its investment manager
         
      By: /s/ Ari Glass
        Ari Glass, Managing Member
         
      Ari Glass
         
      By: /s/ Ari Glass
        Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     
     

     

    CUSIP No. 89268A107

     

    JOINT FILING STATEMENT

    PURSUANT TO RULE 13D-1(K)(1)

     

    The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the common stock held in the form of Units of TradeUP Acquisition Corp. together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

     

    Dated: January 31, 2023

     

      Boothbay Fund Management, LLC
         
      By: /s/ Ari Glass
        Ari Glass, Managing Member
         
      Boothbay Absolute Return Strategies LP
         
      By: Boothbay Fund Management, LLC,
        its investment manager
         
      By: /s/ Ari Glass
        Ari Glass, Managing Member
         
      Ari Glass
         
      By: /s/ Ari Glass
        Individually

     

     

    Get the next $UPTD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $UPTD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPTD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

    Estrella to Begin Trading on NASDAQ Under the Ticker Symbols "ESLA" and "ESLAW" Beginning October 2, 2023 NEW YORK, Sept. 29, 2023 /PRNewswire/ -- Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp. ("UPTD") (NASDAQ:UPTD, UPTDW, UPTDU))), today announced the successful closing of its business combination with Estrella Biopharma, Inc. ("Estrella"), a preclinical-stage biopharmaceutical company developing T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.  The resulting combined company will operate under the name Estrella Immunopharma, Inc. and will be led by Estrella Founder and CEO Dr. Cheng Liu. The com

    9/29/23 10:34:00 AM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

    NEW YORK, Sept. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ:UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from September 19, 2023 to October 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company. The payment for such Monthly Extension Fee was made by Estrella Biop

    9/18/23 5:00:00 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination

    NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ:UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination from August 19, 2023 to September 19, 2023, for each public share that is not redeemed by the Company's stockholders in connection with such extension (collectively, the "Remaining Shares", each, a "Remaining Share"), the Company has deposited into its trust account (the "Trust Account") an aggregate of $37,432.70 (the "Monthly Extension Fee"), representing $0.05 per Remaining Share of the Company. The payment for such Monthly Extension Fee was made by Estrella Biophar

    8/18/23 4:30:00 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $UPTD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Xu Jiandong claimed ownership of 264,388 shares (SEC Form 3)

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/10/23 4:18:19 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Roberts Marsha

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/10/23 4:17:50 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Xu Pei

    3 - Estrella Immunopharma, Inc. (0001844417) (Issuer)

    10/10/23 4:17:25 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $UPTD
    SEC Filings

    View All

    SEC Form 10-Q filed by TradeUP Acquisition Corp.

    10-Q - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/14/24 5:28:53 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by TradeUP Acquisition Corp.

    424B3 - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/12/24 5:02:06 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    TradeUP Acquisition Corp. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Estrella Immunopharma, Inc. (0001844417) (Filer)

    2/2/24 8:30:07 AM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $UPTD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by TradeUP Acquisition Corp.

    SC 13D - Estrella Immunopharma, Inc. (0001844417) (Subject)

    10/27/23 7:27:00 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TradeUP Acquisition Corp. (Amendment)

    SC 13G/A - TradeUP Acquisition Corp. (0001844417) (Subject)

    3/10/23 4:04:07 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by TradeUP Acquisition Corp. (Amendment)

    SC 13G/A - TradeUP Acquisition Corp. (0001844417) (Subject)

    2/14/23 4:49:44 PM ET
    $UPTD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care